The host immune system plays an important role in chronic hepatitis B (CHB), both in viral
clearance and hepatocellular damage. Advances in our understanding of the natural history …

Hepatitis B virus (HBV) chronically infects 250 million people worldwide, resulting in nearly
one million deaths annually. Studies in recent years have significantly improved our …

Background REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg),
enhancing the restoration of functional control of HBV infection by immunotherapy. We …

Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with
considerable variation in clinical presentations, the most common ones being liver disease …

HBsAg seroclearance occurs rarely in the natural history of chronic hepatitis B (CHB)
infection and is associated with improved clinical outcomes. Many factors are associated …

Antiviral polymers are a well-studied class of broad spectrum viral attachment/entry
inhibitors whose activity increases with polymer length and with increased amphipathic …

Background & Aims The hallmarks of chronic HBV infection are a high viral load (HBV DNA)
and even higher levels (> 100-fold in excess of virions) of non-infectious membranous …

Current therapies for chronic hepatitis B virus infection (CHB)–nucleos (t) ide analogue
reverse transcriptase inhibitors and interferons–result in low rates of functional cure defined …

Human hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a
poor prognosis of limited survival. The role of regulatory B cell (Breg), a new important B cell …

Nucleic acid polymers (NAPs) are broad spectrum antiviral agents whose antiviral activity in
hepatitis B virus (HBV) infection is derived from their ability to block the release of the …